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Other than anticoagulation,
what is the best therapy for
those with atrial fibrillation?
■ EVIDENCE-BASED ANSWER
Rate control with long-term anticoagulation is rec-
ommended for most patients with atrial fibrillation
(strength of recommendation [SOR]: A, based on
randomized controlled trials [RCTs]). A rhythm-
control strategy provides no survival or quality-of-
life benefit when compared with rate control and
causes more adverse drug effects and increased
hospitalizations (SOR: A, based on RCTs). 
Non-dihydropyridine calcium-channel blockers
(diltiazem, verapamil) and most beta-blockers are
effective for controlling heart rate both at rest and
during exercise (SOR: A, based on RCTs). Digoxin
is only effective for rate control at rest and should
be reserved for patients with systolic dysfunction
or as an adjunct for those inadequately rate-
controlled on calcium-channel blockers or beta-
blockers (SOR: B, based on RCTs). 
Subgroups in whom rhythm control may be
superior are patients with persistent fatigue and
dyspnea despite ventricular rate control and those
unable to achieve adequate rate control. Both
pharmacologic conversion (SOR: B, based on RCTs)
and direct-current cardioversion (SOR: B, based
on observational studies) are appropriate options
in these patients. 
Long-term anticoagulation is necessary for high-
risk patients even if they are successfully managed
with rhythm control (SOR: A, based on RCTs).
■ EVIDENCE SUMMARY
Five recent RCTs have demonstrated similar 
mortality and cardiovascular morbidity in atrial
fibrillation patients treated with either a rate-
control or rhythm-control strategy.1–5
The AFFIRM trial, the largest (n=4060), was a
nonblinded, randomized, multicenter study with an
average follow-up of 3.5 years.1 The patients were
aged 65 years or older and had at least 1 other risk
factor for stroke. The rhythm-control group was
given an antiarrhythmic medication chosen by the
treating physician, while the rate-control group
was given either a beta-blocker, a calcium-channel
blocker, digoxin, or a combination of these as need-
ed. Heart-rate goals were a resting pulse under 80
beats per minute, and a pulse after a 6-minute
walk under 110 beats per minute. An intention-to-
treat analysis was followed. 
There was no difference between the 2 groups
for the composite endpoints of death, disabling
stroke, disabling anoxic encephalopathy, major
bleeding, or cardiac arrest. A nonsignificant trend
was observed for mortality favoring the rate-con-
trol group (relative risk [RR]=1.15; 95% confi-
dence interval [CI], 0.99–1.34). Quality-of-life
measures were equivalent in the 2 groups at all
points in the study.1
More patients in the rhythm-control group
required hospitalization (number needed to harm
[NNH]=12.3; P<.001) and had adverse drug
effects (P≤.001 for each of pulmonary events
[NNH=18], gastrointestinal events [NNH=17], brady-
cardia [NNH=56], and prolonged QT [NNH=63]).
This trial did not include younger patients without
stroke risk factors, or those with paroxysmal atri-
al fibrillation.1
The 4 other RCTs also found no greater benefit
with a rhythm-control strategy vs rate-control for
most patients with atrial fibrillation.2–5
Two systematic reviews have looked at the effi-
cacy of medications for ventricular rate control in
atrial fibrillation.6,7 The first analyzed 54 trials
involving 17 agents and focused on digoxin calci-
um-channel blockers and beta-blockers. The 
second systematic review evaluated 45 trials with
similar agents. Both reviews were unable to 
perform mathematical pooling due to the hetero-
geneity of the studies. However, both showed
strong evidence for superior ventricular rate 
control at both exercise and rest with verapamil
and diltiazem compared with placebo.6,7
All beta-blockers tested were effective in rate-
control during exercise and most (excluding
labetalol and celiprolol) were effective at rest.6,7
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Digoxin was ineffective during exercise and less
effective than beta-blockers or calcium-channel
blockers at rest.6–8 The combination of digoxin
plus a calcium-channel blocker or beta-blocker
may have increased benefit compared with either
drug alone.6 Evidence was insufficient to recom-
mend propafenone, clonidine, or amiodarone for
rate control.7
In select patients, a rhythm-control approach
may be desirable. A meta-analysis of 60 RCTs
evaluated 8 drugs for acute cardioversion.
Ibutilide, flecainide, dofetilide, propafenone, and
amiodarone were found to have the strongest evi-
dence of efficacy.6 There was moderate evidence
for quinidine and insufficient evidence for disopy-
ramide and sotalol.6 Studies of pharmacologic
conversion suffer from small sample size, short
follow-up, and variable duration of atrial fibrilla-
tion.6 A review of limited research reveals an 80%
to 85% immediate success rate for DC cardiover-
sion, with rare side-effects of ventricular tachy-
cardia, transient AV node dysfunction, and signif-
icant skin blistering.6
For patients who elect a rhythm-control
approach, RCTs demonstrate the need for contin-
ued long-term anticoagulation in high-risk patients
even if they are maintained in sinus rhythm.1,4,5
(High-risk patients are defined as those aged >65
years, or those <65 years with 1 or more stroke
risk factors: diabetes, hypertension, heart failure,
prior transient ischemic attack or stroke or sys-
temic embolism, or echocardiographic evidence of
a left atrium >50 mm, a shortening fraction <25%,
or an ejection fraction <40%.) 
■ RECOMMENDATION FROM OTHERS
The American Academy of Family Practice/
American College of Physicians’ clinical guide-
lines support a rate-control strategy for most
patients with atrial fibrillation and recommend
atenolol, metoprolol, diltiazem, or verapamil as
the first-choice drugs.8 Digoxin is recommended
as a second-line agent. DC cardioversion and
pharmacologic conversion for patients who desire
a rhythm-control strategy are described as
“appropriate options.”8
Kara Cadwallader, MD, Family Practice Residency of
Idaho, University of Washington, Seattle; Terry Ann
Jankowski, MLS, University of Washington Health
Sciences Libraries, Seattle
■ CLINICAL COMMENTARY:
Rate control best for atrial fibrillation
AFFIRMed at last, it’s rate-controlling and not
rhythm-controlling drugs that get the evidence-
based nod for most types of atrial fibrillation.
While rate and rhythm control were equally
efficacious in most patient-oriented outcomes,
the antiarrhythmics sent more people to the
hospital and, potentially, killed more people
than the rate controlling medications. The
antiarrhythmics, especially amiodarone,9 do
have a place in maintaining sinus rhythm in
select patients with atrial fibrillation; but that
role is limited and may be best managed with
the help and support of a cardiologist.
The atrial fibrillation evidence also suggests
that we need to place beta-blocker and non-
dihydropyridine calcium-channel blockers (ie,
verapamil and diltiazem) as first-line choices
for rate-control therapy. Digoxin still has a
place in our medical armamentarium; but its
role is as an adjunct or backup to the blockers
for most patients. 
Clint Koenig, MD, MS, Fulton, Missouri
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■ EVIDENCE SUMMARY
Superficial thrombophlebitis refers to erythema,
pain, induration, and other findings of inflamma-
tion in superficial veins, usually due to infection
or thrombosis. Typically, SVTP is localized prob-
lem, but some lower-extremity SVTP is associat-
ed with increased risk of DVT and PE, particular-
ly the long saphenous vein. This review will not
address thrombosis in the superficial femoral
vein, a portion of the deep venous system, which
requires full DVT therapy.1
Since saphenous vein thrombosis above the
knee is associated with DVT and PE, 1 systemat-
ic review looked at papers comparing anticoagula-
tion (IV heparin followed by 6 weeks to 6 months
of warfarin) with surgical ligation of the saphe-
nous vein (either alone or combined with vein
stripping or with vein stripping and perforator lig-
ation).1 The review included primarily case series
with widely varying protocols. According to the
authors, the data “suggests that medical manage-
ment with anticoagulants is somewhat superior”
to surgery for preventing DVT and PE. However,
the fewest extensions of SVTP occurred when vein
ligation was combined with stripping of the throm-
bosed vein and interruption of perforators. 
In a more recent trial, patients randomized 
to subcutaneous heparin at 12,500 units twice
daily for a week followed by 10,000 units 
twice daily had fewer vascular complications of
proximal saphenous vein thrombosis than those
receiving heparin at 5000 units twice daily 
(6/30 in the low-dose group and 1/30 in the high-
dose group; P<.05; number needed to treat
[NNT]=6).2 There were no bleeding complica-
tions in either group.
One large double-blind randomized controlled
trial compared tenoxicam (an NSAID available in
Canada, similar to piroxicam), enoxaparin
(Lovenox), and placebo for 8 to 12 days in 427
patients with SVTP of the leg measuring 5 cm or
more.3 Patients were also treated with compression
hose. Patients who required immediate anticoagu-
lation or venous ligation were excluded. Within 3
months, 35% of patients taking placebo developed
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What is the best therapy 
for superficial
thrombophlebitis?
■ EVIDENCE-BASED ANSWER
For proximal saphenous vein thrombosis, anti-
coagulation is more effective than venous ligation
(with or without stripping) in preventing deep
venous thrombosis (DVT) and pulmonary embolus
(PE) (strength of recommendation [SOR]: C, qual-
itative systematic review of primarily case series). 
For patients with superficial venous throm-
bophlebitis (SVTP) distal to the saphenous vein
of the thigh, tenoxicam (a nonsteroidal anti-
inflammatory agent [NSAID]) and low-molecu-
lar-weight heparin are similarly effective for
reducing extension and subsequent DVT when
administered along with compression therapy
(SOR: B, 1 randomized controlled trial). Oral or
topical NSAIDs, topical heparin, and topical
nitroglycerin all alleviate symptoms and speed
resolution of SVTP caused by infusion catheters
(SOR: B, smaller, occasionally conflicting ran-
domized trials). 
